Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Safety and body processing of ANB033 in adults with eosinophilic esophagitis or celiac disease
Tests how safe ANB033 is and how the body handles it in adults.
Key facts
- Who runs it
- First Tracks Biotherapeutics Inc.
- Where
- Amsterdam, Dordrecht, and Groningen, NetherlandsSee the 3 sitesAlso in 6 other countries, 16 sites
- Trial code
- Registry title
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ANB033
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 48 people, planned
- Started
- 14 Nov 2025
- Expected to end
- 31 Dec 2026
- Type of study
- Interventional
- Record updated
- 2 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults to test single and multiple doses of ANB033. It is linked to eosinophilic esophagitis (EoE) and celiac disease, and healthy volunteers can join.
- Age
- 18 years and older
- Sex
- All sexes
Where in Netherlands
Also in 6 other countries, 16 sites
- Amsterdam UMC StichtingAmsterdam, NetherlandsTaking people
- Albert Schweitzer ZiekenhuisDordrecht, NetherlandsTaking people
- CTC Netherlands B.V.Groningen, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Safety and body processing of ANB033 in adults with eosinophilic esophagitis or celiac diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 2 October 2026